- Home
- ARDX
ARDX
Ardelyx Inc.
as 07-25-2025 4:00pm EST
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FREMONT |
| Market Cap: | 882.9M | IPO Year: | 2014 |
| Target Price: | $10.17 | AVG Volume (30 days): | 4.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.21 - $7.18 | Next Earning Date: | 08-04-2025 |
| Revenue: | $361,706,000 | Revenue Growth: | 127.33% |
| Revenue Growth (this year): | 11.39% | Revenue Growth (next year): | 32.84% |
Stock Insider Trading Activity of Ardelyx Inc. (ARDX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MOTT DAVID M | ARDX | Director | Jun 16 '25 | Buy | $3.63 | 200,000 | $725,880.00 | 2,896,871 | |
| MOTT DAVID M | ARDX | Director | Jun 9 '25 | Buy | $3.69 | 200,000 | $737,260.00 | 2,896,871 | |
| RAAB MICHAEL | ARDX | President & CEO | May 20 '25 | Sell | $4.08 | 46,817 | $191,078.90 | 1,547,937 | |
| Renz Justin A | ARDX | Chief Financial Officer | May 20 '25 | Sell | $4.08 | 7,218 | $29,459.55 | 416,089 | |
| Williams Laura A | ARDX | Chief Medical Officer | May 20 '25 | Sell | $4.08 | 6,421 | $26,206.67 | 402,583 | |
| Kelliher Mike | ARDX | See Remarks | May 20 '25 | Sell | $4.08 | 14,522 | $59,270.09 | 282,158 | |
| GRAMMER ELIZABETH A | ARDX | See Remarks | May 20 '25 | Sell | $4.08 | 5,992 | $24,455.75 | 311,731 | |
| Foster Eric Duane | ARDX | Chief Commercial Officer | May 20 '25 | Sell | $4.08 | 2,507 | $10,232.07 | 316,806 | |
| MOTT DAVID M | ARDX | Director | May 15 '25 | Buy | $3.29 | 100,000 | $329,120.00 | 2,896,871 | |
| MOTT DAVID M | ARDX | Director | May 2 '25 | Buy | $4.22 | 381,377 | $1,610,936.45 | 2,896,871 |
Latest Ardelyx Inc. News
ARDX Breaking Stock News: Dive into ARDX Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
Exploring Three High Growth Tech Stocks in the US Market
Simply Wall St.
a month ago
Exploring US High Growth Tech Stocks For Potential Opportunities
Insider Monkey
a month ago
H.C. Wainwright Initiates Coverage of Ardelyx (ARDX) Stock, Gives Buy
Simply Wall St.
a month ago
US High Growth Tech Stocks To Watch In June 2025
Insider Monkey
a month ago
Leerink Partners Maintains a Buy Rating on Ardelyx (ARDX) With a $10 PT
Simply Wall St.
a month ago
High Growth Tech Stocks To Watch In US June 2025
Simply Wall St.
a month ago
Ardelyx Leads The Pack Of 3 Promising Penny Stocks
Simply Wall St.
a month ago
Exploring US High Growth Tech Stocks To Watch In June 2025
Compare ARDX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARDX Ardelyx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.